Latest Regulatory Engagement News

Page 2 of 24
Nexsen Limited (ASX:NXN) reported a 30% rise in net loss to $6.55 million for FY26, driven by ongoing investment in its Group B Streptococcus rapid diagnostic and Asia-Pacific growth initiatives following its October 2025 IPO.
Ada Torres
Ada Torres
31 Aug 2026
PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.
Ada Torres
Ada Torres
28 Aug 2026
Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.
Victor Sage
Victor Sage
26 Aug 2026
Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.
Ada Torres
Ada Torres
26 Aug 2026
Evolution Energy Minerals has regained full rights to its Chilalo Graphite Project licence in Tanzania, clearing a significant regulatory hurdle and reaffirming its target to begin production by October 2027.
Maxwell Dee
Maxwell Dee
26 Aug 2026
NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.
Ada Torres
Ada Torres
25 Aug 2026
Prescient Therapeutics launches a $7 million Share Purchase Plan at an 18.8% discount to fund advancement of its PTX-100 cancer therapy beyond a key 2026 Dose Optimisation Committee review.
Ada Torres
Ada Torres
25 Aug 2026
AdAlta Limited (ASX:1AD) has progressed its ‘East to West’ cellular immunotherapy strategy by securing its first CAR-T asset, advancing Australian manufacturing and US FDA regulatory engagement, while raising A$5.3 million in FY2026 and reporting a net loss of $4.68 million.
Ada Torres
Ada Torres
21 Aug 2026
NZX Limited reported a robust first half of 2026 with operating earnings up 9.4% and net profit rising 18%. The exchange strengthened its funds management and wealth administration arms, relaunched equity derivatives, and declared a higher interim dividend. A new CEO is set to take the helm in September.
Claire Turing
Claire Turing
20 Aug 2026
Investigator Silver has hit a key development milestone, lodging a Mining Lease Application for its Paris Silver Project in South Australia. This step follows extensive technical work and stakeholder engagement, setting the stage for approvals and project development in 2027.
Maxwell Dee
Maxwell Dee
19 Aug 2026
Taiko Critical Minerals has successfully closed a NZ$2.5 million Share Purchase Plan, issuing over 10 million shares at NZ$0.25 each to support the development of its Barrytown Critical Minerals Project.
Maxwell Dee
Maxwell Dee
19 Aug 2026
Vector Limited (NZX:VCT) posted a 55% jump in net profit to $240 million for FY2026, driven by a 20% rise in adjusted EBITDA and a record $544 million capital investment in Auckland’s electricity network.
Maxwell Dee
Maxwell Dee
18 Aug 2026

Browse the archive

Full archive